Physician profile
Thomas Hilton
NPI 1316949746
$4,406.55
in general payments reported to CMS, 2019-2025
32 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $549 · 2021: $988 · 2022: $1,342 · 2023: $296 · 2024: $395 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $805.38 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $462.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $410.65 | 2019-2022 | |
| Pfizer INC. | $330.40 | 2020-2025 | |
| Abbott Laboratories | $306.73 | 2021-2024 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $251.38 | 2022-2025 | |
| Cvrx, INC. | $189.37 | 2021-2022 | |
| Novo Nordisk INC | $170.34 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $158.30 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $153.91 | 2019-2022 | |
| Amarin Pharma, INC. | $144.88 | 2020-2021 | |
| Medtronic, INC. | $111.94 | 2022 | |
| Edwards Lifesciences Corporation | $109.45 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $109.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.13 | 2019-2025 | Wainua, Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $95.06 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.21 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $65.45 | 2021-2024 | Verquvo |
| Ge Healthcare | $59.02 | 2023 | |
| Novartis Pharmaceuticals Corporation | $57.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.71 | 2019-2021 | |
| Lilly USA, LLC | $25.33 | 2024 | Zepbound |
| Atricure, INC. | $21.97 | 2024 | |
| Impulse Dynamics (USA) INC. | $20.98 | 2022 | |
| Ionis Pharmaceuticals, INC. | $19.68 | 2025 | Tryngolza |
| Vivus LLC | $18.23 | 2021 | |
| Gilead Sciences, INC. | $16.32 | 2019 | |
| Boston Scientific Corporation | $15.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.03 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.65 | 2022 | |
| Bardy Diagnostics, INC. | $12.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.